Видео ютуба по тегу Lenvatinib

Dr. Finn on Role of Lenvatinib in HCC Treatment Paradigm
Dr. Finn on Role of Lenvatinib in HCC Treatment Paradigm
Lenvatinib in Advanced DTC
Lenvatinib in Advanced DTC
Dr. Taylor Discusses the Toxicities and Impact of Lenvatinib in the SELECT Trial
Dr. Taylor Discusses the Toxicities and Impact of Lenvatinib in the SELECT Trial
Dr. Wirth on the Use of Lenvatinib in Hypertensive Patients With Thyroid Cancer
Dr. Wirth on the Use of Lenvatinib in Hypertensive Patients With Thyroid Cancer
Breaking New Ground in Thyroid Cancer Treatment: The Promise of Lenvatinib
Breaking New Ground in Thyroid Cancer Treatment: The Promise of Lenvatinib
Dr. Wirth Discusses the Safety Profile of Lenvatinib as Seen in the SELECT Trial
Dr. Wirth Discusses the Safety Profile of Lenvatinib as Seen in the SELECT Trial
Lenvatinib in Thyroid Cancer With and Without VEGF-Targeted Therapy
Lenvatinib in Thyroid Cancer With and Without VEGF-Targeted Therapy
Implication of Upfront Lenvatinib in HCC
Implication of Upfront Lenvatinib in HCC
Dr. Bastholt on Lenvatinib in Thyroid Cancer
Dr. Bastholt on Lenvatinib in Thyroid Cancer
Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma
Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma
Phase III Findings for Lenvatinib in HCC
Phase III Findings for Lenvatinib in HCC
Lenvatinib in Renal Cell Carcinoma
Lenvatinib in Renal Cell Carcinoma
Significant Side Effects
Significant Side Effects
24mg versus 18mg starting dose of lenvatinib for differentiated thyroid cancer
24mg versus 18mg starting dose of lenvatinib for differentiated thyroid cancer
Prof. S. I.Sherman - Lenvatinib and its use
Prof. S. I.Sherman - Lenvatinib and its use
Effect of Age and Lenvatinib on OS in Thyroid Cancer
Effect of Age and Lenvatinib on OS in Thyroid Cancer
Dr. Cheng on Phase III Findings of Lenvatinib in HCC
Dr. Cheng on Phase III Findings of Lenvatinib in HCC
Lenvatinib Perspective program
Lenvatinib Perspective program
Discussing the Phase II Study of Lenvatinib/Pembrolizumab in Metastatic ccRCC
Discussing the Phase II Study of Lenvatinib/Pembrolizumab in Metastatic ccRCC
Dr. El-Khoueiry on Choosing Between Lenvatinib and Sorafenib in HCC
Dr. El-Khoueiry on Choosing Between Lenvatinib and Sorafenib in HCC
Lenvatinib Pembrolizumab in RCC, the CLEAR trial with Karine Tawagi
Lenvatinib Pembrolizumab in RCC, the CLEAR trial with Karine Tawagi
Effect of Age and Lenvatinib Treatment on OS for Patients With Thyroid Cancer
Effect of Age and Lenvatinib Treatment on OS for Patients With Thyroid Cancer
Dr. Makker on Safety Signals With Lenvatinib and Pembrolizumab in Endometrial Cancer
Dr. Makker on Safety Signals With Lenvatinib and Pembrolizumab in Endometrial Cancer
Combining lenvatinib & pembrolizumab for non-clear cell RCC: KEYNOTE-B61 study rationale
Combining lenvatinib & pembrolizumab for non-clear cell RCC: KEYNOTE-B61 study rationale
Эффективность применения схемы «Ленватиниб + Эверолимус»
Эффективность применения схемы «Ленватиниб + Эверолимус»